Benign Prostatic Hyperplasia is a non-cancerous increase in the number of cells within the prostate that commonly develops with ageing. The term describes histological hyperplasia rather than simply an enlarged prostate on imaging, although the two commonly occur together. Benign Prostatic Hyperplasia predominantly affects tissue in and around the transition zone of the prostate and can increase resistance to urine flow through the prostatic urethra. The resulting bladder outlet obstruction may contribute to lower urinary tract symptoms, including difficulty starting urination, weak stream, intermittency, prolonged voiding and incomplete emptying. Storage symptoms such as frequency, urgency and nocturia can also occur, partly because the bladder adapts to chronic obstruction.
The development of Benign Prostatic Hyperplasia is strongly associated with ageing and requires functioning testes or androgenic signalling over the relevant period of life. Dihydrotestosterone, produced from testosterone by the enzyme 5-alpha-reductase, has an important role in prostate growth. Hyperplasia involves both stromal and epithelial components, and the degree of microscopic hyperplasia does not directly determine symptom severity. A relatively modest increase in prostate tissue can cause substantial obstruction in one person because of its anatomical position, while another person with a larger prostate may have relatively mild symptoms. This explains why prostate volume, urinary flow and symptom burden must be considered as related but distinct measurements.
Benign Prostatic Hyperplasia produces two broad categories of lower urinary tract symptoms. Voiding symptoms occur during urination and can include hesitancy, weak stream, intermittency, straining and incomplete emptying. Storage symptoms occur while the bladder is filling and include increased frequency, urgency and nocturia. Chronic obstruction can lead to compensatory changes in bladder muscle, and advanced obstruction may contribute to urinary retention, recurrent infections, bladder stones or upper urinary tract effects. However, symptoms can also result from primary bladder dysfunction or other disorders, so a clinical diagnosis should not be based solely on symptom pattern. Structured symptom questionnaires can quantify severity and monitor treatment response but do not by themselves identify the underlying anatomical mechanism.
Assessment of Benign Prostatic Hyperplasia begins with a history of urinary symptoms, their duration, severity and effect on daily life. Medication review is important because some drugs can worsen urinary retention or alter bladder function. Examination may include abdominal assessment and, where appropriate, digital rectal examination. Urinalysis can help identify infection, blood or other abnormalities, while blood tests may assess kidney function or other relevant parameters.
PSA testing may be considered in appropriate circumstances because prostate cancer can coexist with benign enlargement and because prostate volume and other factors influence PSA concentration. Uroflowmetry, post-void residual measurement and imaging may be used selectively, particularly when symptoms are severe, diagnosis is uncertain or invasive treatment is being considered.
Management ranges from conservative monitoring to medication and procedural intervention. When symptoms are mild or not particularly troublesome, watchful waiting with lifestyle and behavioural measures may be appropriate. Alpha-1 adrenergic receptor blockers reduce smooth-muscle tone in the prostate and bladder neck and can improve urinary flow relatively quickly, while 5-alpha-reductase inhibitors reduce conversion of testosterone to dihydrotestosterone and can gradually reduce prostate volume and the risk of progression in suitable patients. Combination treatment may be used when both rapid symptom relief and reduction of progression risk are relevant. Other medicines can target storage symptoms in selected patients. Treatment selection depends on prostate characteristics, symptom pattern, cardiovascular status, adverse-effect risk and patient priorities.
Procedural and surgical treatments are considered when symptoms remain troublesome despite medication, when medication is unsuitable, or when complications of obstruction occur. Established approaches include transurethral resection of the prostate and other endoscopic techniques, while newer minimally invasive procedures use different mechanisms to remove, ablate or displace obstructing tissue. The choice depends on prostate size and anatomy, operator expertise, equipment availability, sexual and urinary priorities, comorbidities and evidence for the specific technique.
Potential complications vary by procedure and can include bleeding, infection, temporary or persistent urinary symptoms, urethral narrowing, bladder-neck problems, ejaculatory changes, erectile effects or the need for further treatment. The objective is not simply to reduce prostate size but to improve clinically meaningful urinary function while balancing procedural risks.
Benign Prostatic Hyperplasia can progress over time, but progression is variable. Some people experience stable symptoms, while others develop worsening obstruction, acute urinary retention or complications such as infections, bladder stones and impaired upper urinary tract function. Chronic obstruction can increase the workload on the bladder and produce structural changes that may persist even after the obstruction is relieved. Benign enlargement can also coexist with prostate cancer, prostatitis or other urological conditions. The word “benign” means non-malignant and does not mean that symptoms are necessarily harmless or trivial. Conversely, not every enlarged prostate requires treatment, and treatment is generally directed at bothersome symptoms, clinically important obstruction or complications rather than prostate size alone.
Benign Prostatic Hyperplasia is frequently confused with prostate cancer because both are common in older men and both can affect PSA concentration or urinary function, but they are biologically distinct conditions. Benign enlargement does not transform directly into prostate cancer, although both can occur in the same individual. It is also incorrect to equate all lower urinary tract symptoms with Benign Prostatic Hyperplasia because bladder overactivity, neurological disease, infection and urethral disorders can produce similar complaints. Another misconception is that treatment necessarily restores completely normal urination; long-standing bladder dysfunction may persist even after obstruction is relieved. Accurate assessment therefore distinguishes anatomical prostate enlargement, histological hyperplasia, functional obstruction and symptom severity rather than treating them as interchangeable concepts.
